In the news

As lifespans grow longer, targeted medical technology can help people live better, healthier lives—with fewer pills.

Dr. Janar Sathananthan, president, Interventional Cardiology, discusses the FRACTURE IDE trial, which met its primary endpoints for the SEISMIQ™ 4CE Coronary IVL Catheter in severely calcified coronary disease. The result underscores Boston Scientific’s broader intravascular lithotripsy commercialization strategy and differentiated cardiology solutions.

Karen Carlson’s incontinence kept her housebound for years despite various failed treatments. The Axonics™ Sacral Neuromodulation Therapy helped relieve her symptoms, restoring her active life.

This sponsored article explores how physicians are helping patients living with atrial fibrillation address two health issues at the same time: irregular heart rhythms and stroke risk.

The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.